CA2764499A1 - Interlaced method for treating cancer or a precancerous condition - Google Patents

Interlaced method for treating cancer or a precancerous condition Download PDF

Info

Publication number
CA2764499A1
CA2764499A1 CA2764499A CA2764499A CA2764499A1 CA 2764499 A1 CA2764499 A1 CA 2764499A1 CA 2764499 A CA2764499 A CA 2764499A CA 2764499 A CA2764499 A CA 2764499A CA 2764499 A1 CA2764499 A1 CA 2764499A1
Authority
CA
Canada
Prior art keywords
dosage
tumor
cell cycle
phase
cancerous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2764499A
Other languages
English (en)
French (fr)
Inventor
Lloyd S. Gray
Timothy Macdonald
Joel Linden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cavion LLC
Original Assignee
Tau Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tau Therapeutics LLC filed Critical Tau Therapeutics LLC
Publication of CA2764499A1 publication Critical patent/CA2764499A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2764499A 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition Abandoned CA2764499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18465809P 2009-06-05 2009-06-05
US61/184,658 2009-06-05
PCT/US2010/037437 WO2010141842A2 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition

Publications (1)

Publication Number Publication Date
CA2764499A1 true CA2764499A1 (en) 2010-12-09

Family

ID=43298556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2764499A Abandoned CA2764499A1 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition

Country Status (15)

Country Link
US (2) US20120088807A1 (enExample)
EP (1) EP2437749B8 (enExample)
JP (2) JP5806210B2 (enExample)
KR (2) KR20120030112A (enExample)
CN (2) CN106177963A (enExample)
AU (1) AU2010256442B2 (enExample)
CA (1) CA2764499A1 (enExample)
DK (1) DK2437749T3 (enExample)
ES (1) ES2661216T3 (enExample)
IL (2) IL216443A (enExample)
MX (1) MX344725B (enExample)
PL (1) PL2437749T3 (enExample)
SG (3) SG176678A1 (enExample)
WO (1) WO2010141842A2 (enExample)
ZA (1) ZA201108909B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
EP2755674A4 (en) * 2011-09-12 2015-04-08 Tau Therapeutics Llc ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS
US11642353B2 (en) 2014-02-06 2023-05-09 The Procter & Gamble Company Hair care composition comprising antidandruff agent and polyquaternium-6
US11058624B2 (en) 2014-02-06 2021-07-13 The Procter And Gamble Company Hair care composition comprising cationic polymers and anionic particulates
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
EP3615521A4 (en) 2017-04-26 2021-02-17 Cavion, Inc. METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
JP7480131B2 (ja) 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
CN118217178A (zh) 2018-10-04 2024-06-21 宝洁公司 包含水不溶性固体有机化合物的个人护理组合物
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
US20060000320A1 (en) * 2004-06-30 2006-01-05 Hutton William M Ratchet wrench tool assembly for underground work and process of using
CA2576186A1 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CA2576191C (en) * 2004-08-20 2013-03-19 University Of Virginia Patent Foundation T type calcium channel inhibitors
CN100546579C (zh) * 2006-12-30 2009-10-07 南京工业大学 替莫唑胺聚乳酸纳米微球与制剂及其制备方法
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof

Also Published As

Publication number Publication date
JP5806210B2 (ja) 2015-11-10
SG10201402863PA (en) 2014-10-30
WO2010141842A2 (en) 2010-12-09
PL2437749T3 (pl) 2018-04-30
SG176678A1 (en) 2012-01-30
CN106177963A (zh) 2016-12-07
DK2437749T3 (da) 2018-01-29
ES2661216T3 (es) 2018-03-28
EP2437749A2 (en) 2012-04-11
MX344725B (es) 2017-01-05
EP2437749B8 (en) 2018-02-21
IL216443A (en) 2016-11-30
CN102458416A (zh) 2012-05-16
EP2437749B1 (en) 2017-12-20
KR20120030112A (ko) 2012-03-27
WO2010141842A3 (en) 2011-04-21
US20120088807A1 (en) 2012-04-12
JP2016028058A (ja) 2016-02-25
KR101905050B1 (ko) 2018-10-08
SG10201810806UA (en) 2019-01-30
MX2011012940A (es) 2012-04-20
EP2437749A4 (en) 2013-04-17
IL248482A0 (en) 2016-12-29
JP6159958B2 (ja) 2017-07-12
US20180228822A1 (en) 2018-08-16
ZA201108909B (en) 2013-02-27
JP2012528890A (ja) 2012-11-15
AU2010256442A1 (en) 2012-01-19
KR20170097237A (ko) 2017-08-25
AU2010256442B2 (en) 2016-07-21
IL216443A0 (en) 2012-02-29
IL248482B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
EP2437749B1 (en) Interlaced method for treating cancer or a precancerous condition
Guise Antitumor effects of bisphosphonates: promising preclinical evidence
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
US8536137B2 (en) Methods for treating nucleoside-induced pain
JP2015505313A (ja) 癌を治療するための併用療法
RU2764175C1 (ru) Бифункциональные композиции для лечения рака
CA2870138A1 (en) Glufosfamide combination therapies for cancer
US20240082177A1 (en) Use of cysteamine and derivatives thereof to suppress tumor metastases
WO2016166761A1 (en) Combination therapies and uses thereof in the treatment of cancer
CN119235866B (zh) Sn38和az20在制备治疗脑干胶质瘤药物中的用途
HK1168764B (en) Interlaced method for treating cancer or a precancerous condition
HK1168764A (en) Interlaced method for treating cancer or a precancerous condition
Ozkan et al. Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine
CN109069478B (zh) Z-亚丁基苯酞于活化自体免疫系统的应用
CN111407748A (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
WO2017042314A1 (en) Methods and pharmaceutical composition for the treatment of post-traumatic epilepsies
TW201513871A (zh) 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法
EP1629839A1 (en) Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
JP2024113036A (ja) 医薬組成物及び組み合わせ物
Sørensen et al. 218 Phase II study of bi-weekly paclitaxel (P) and cisplatin (C) for non-resectable non small-cell lung cancer (NSCLC)
Arita et al. 219 Prediction of carboplatin clearance on Japanese lung cancer patients
Zaniboni et al. 220 Taxol, ifospamide and carboplatin for NSCLC: A phase II study
MX2013004423A (es) Uso de cisteamina y derivados de la misma para suprimir metastasis de tumor.
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1082421A (en) Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150603

FZDE Discontinued

Effective date: 20220617